![Loading Events](https://www.rbtc.tech/wp-content/plugins/the-events-calendar/src/resources/images/tribe-loading.gif)
- This event has passed.
Beer & Biotech
September 21, 2022 @ 4:30 pm - 6:00 pm
![](https://www.rbtc.tech/wp-content/uploads/2022/08/tiny-cargo-co.jpg)
Get to know the Tiny Cargo Company Inc — a TechNite award winner and RAMP alumni company.
Dr. Rob Gourdie and Dr. Spencer Marsh will talk about their path of innovation and future steps for the company. (They are doing some pretty cool things!)
The Tiny Cargo Company Inc is innovating a drug delivery platform comprising easy-to-administer, non-immunogenic exosomes/small extracellular vesicles (mEVs) purified in industrial quantities from cow milk that are loaded with a drug mitigating radiation injury, with multi-use potential for other clinically important injury and disease scenarios, including myocardial infarction (MI) and sepsis. Tiny Cargo will speak about the current products in our pipeline, but also about our path through spin-out from the FBRI to current NSF-funded Company, with a focus on collaborations and opportunities in the area.
Beer & Biotech is an ecosystem-building series that will bring together investors, physicians, academics, inventors, startups, and state and regional leaders who are influential in the biotechnology industry. Each event in the year-long series will feature a local, regional, or national speaker and include plenty of time for networking and beverages at the host brewery.
ABOUT THE SPEAKERS
Dr. Gourdie is Professor and center director at the Fralin Biomedical Research Institute, at Virginia Tech. He is an elected fellow of the American Institute of Medical and Biological Engineers and the American Heart Association and was recently awarded a prestigious 7-year NIH R35 Outstanding Investigator award. Dr. Gourdie specializes in translational research of the gap junction protein connexin43 (Cx43), with numerous peptidic drugs invented in his laboratory. In addition to Tiny Cargo, Dr. Gourdie has spun off three other successful companies, including First String Research Inc. (now Xequelbio) – a $120m clinical-stage company employing 15, who are currently in Phase III clinical trials. Dr. Gourdie provides technical and commercial experience, a strong record of accomplishment in mentoring and budding biomedical entrepreneurs.
Dr. Marsh is the lead investigator on Tiny Cargo’s mEV technology and is currently leading scientific efforts as well as the efforts to obtain grants and other funding. Dr. Marsh wrote and submitted the NSF STTR Phase I application that was funded in June of 2022, the JLABS QuickFire Challenge which led to JLABS residency, and took Tiny Cargo through the local RAMP incubator program. Dr. Marsh is a trained biomedical engineer specializing in process engineering, biomedical engineering, and did his Ph.D. work on exosome research. Dr. Marsh pioneered the research that led to both of Tiny Cargo’s patents (mEV isolation, mEV loading), and leads the team in animal trials for each of our current aims.